Sandoz Group AG
SDZNY - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$43.84B
Close$
Earnings Call Q4 2025
February 25, 2026 - AI Summary
Strong Financial Performance: Sandoz reported net sales growth of 5% in 2025, reaching $11.1 billion, with a core EBITDA margin expansion of 160 basis points to 21.7%. This strong performance was driven by successful biosimilar launches, which grew by 13% and now represent 30% of total sales.
Biosimilars Growth and Market Position: The company launched several significant biosimilars, including denosumab products Wyost and Jubbonti, which are expected to continue strong performance into 2026. Notably, denosumab is projected to have a flying start, although competition may affect pricing dynamics.
Capital Expenditure and Future Investments: Sandoz invested approximately $700 million in 2025, primarily focused on biosimilars capabilities. Expenditure is expected to peak at around $1.1 billion in 2026, supporting the construction of a new biosimilars hub and integrating Just-Evotec Biologics, which could enhance production capacity.
Exclusive for Stockcircle Pro members
Sign up
$20.65
79.5% downside
Current Fair Value
79.5% downsideOvervalued by 79.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $43.84 Billion |
|---|---|
| Enterprise Value | $48.79 Billion |
| Annual dividend | $1.02 |
| Dividend yield | 0.95% |
| Earnings per Share | $2.13 |
| Beta | 0.53 |
| Outstanding Shares | 434,900,000 |
Return
| Return on Equity | 7.75% |
|---|---|
| Return on Assets | 3.06% |
| Return on Invested Capital | 14.36% |
Valuation & Multiples
| P/E Ratio | 68.52 |
|---|---|
| PEG | -107.94 |
| Price to Sales | 2.29 |
| Price to Book Ratio | 5.04 |
| Enterprise Value to Revenue | 2.51 |
| Enterprise Value to EBIT | 23.51 |
| Enterprise Value to Net Income | 69 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 0.69 |
Revenue Sources
No data
Last Earnings Call
Report Date
March 3, 2026
EPS
$1.58
ReportedRevenue
$7.38 B
Est. $2.78 BInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▼ 0.03% |
|---|---|
| Total Invested | $10.53M▼ 54.56% |
| Investors Holding | 22▼ 7.00% |
About Sandoz Group AG
22,049 employees
CEO: Mr. Richard Saynor
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides prot...